Coronary Microvascular Dysfunction
43
16
18
14
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.3%
1 terminated out of 43 trials
93.3%
+6.8% vs benchmark
9%
4 trials in Phase 3/4
29%
4 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (43)
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
Coronary Flow During Rapid Heart Rates
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)
The DISCOVER INOCA Prospective Multi-center Registry
Improving Coronary Vascular Health in Women
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.
Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
COronary Microcirculation and Troponin Elevation in Septic Shock
Super Saturated Oxygen (SSO2) Therapy in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Action on Coronary Microcirculation Dysfunction
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries
Microvascular Dysfunction in Adults with Congenital Heart Disease and the Effect of Exercise Training
Insulin Resistance and Coronary Microvascular Dysfunction in Patients with Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Mechanisms Behind Microvascular Dysfunction in INOCA
Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)